
Exciting news for young PFIC patients in the United States! The U.S. Food and Drug Administration has approved a label expansion for maralixibat. The expanded label includes use in PFIC patients 12 months and older as well as the higher concentration formulation evaluated in the MARCH Phase 3 study. Congratulations to the Mirum Pharmaceuticals team